OpGen > Company > Investors

Investors

Investor Inquiries

Eric Winzer, CFO
OpGen, Inc.
InvestorRelations@OpGen.com
P  240.813.1289

OpGen, Inc.

OpGen Incorporated is a privately owned company, founded in 2002 by the Wisconsin Alumni Research Foundation (WARF) as a Delaware corporation. Current investors include CHL Medical Partners, Highland Capital Partners, Versant Ventures, Mason Wells, In-Q-Tel and jVEN Capital LLC.

Please see the OpGen company overview for description of OpGen technologies and markets.

 

CHL Medical Partners

CHL Medical Partners is a leading venture capital firm focused on partnering with entrepreneurs and inventors in creating and financing innovative seed and early-stage companies in the biotechnology, molecular diagnostics, healthcare services and medical device sectors. The five partners of CHL Medical Partners have an average of 18 years of investment experience devoted to the founding and nurturing of life science companies. Our team is well-known among industry observers and life science investment professionals for identifying and validating visionary scientific and healthcare ideas and creating business with extraordinary market potential. Collectively, we have invested in and grown more than 80 start ups, establishing a notable track record of building prominent companies with products and services that significantly improve patient care. With committed capital of more than $300 million, we are continually reviewing promising translational medical research and innovative healthcare service models for the next high-value, pioneering investment opportunities. www.chlmedical.com

 

Highland Capital Partners

Highland Capital Partners was founded with the mission of helping great people build great companies. Since its inception in 1988, the firm has taken a sector-focused approach to investing in exceptional communications, consumer, digital media, healthcare and information technology companies. With more than $3 billion of committed capital and offices in Boston, Silicon Valley, Shanghai and Geneva, Highland has invested in and worked to create such firms as Ask Jeeves, Avid Technology, CheckFree, Conor Medsystems, Continental Cable, Helicos BioSciences, lululemon athletica, Lycos, MapQuest, Navic Networks, Ocular Networks, Odyssey Healthcare, P.A. Semi, Quigo, Starent Networks, Sybase, Telica and VistaPrint. www.hcp.com

 

Versant Ventures

Versant Ventures consists of a seasoned team of twelve managing directors collectively possess more than 130 years of venture capital investing experience and more than 150 years of operating experience. Versant is committed to transforming healthcare through innovation, and invests in all segments of healthcare including, medical devices, life sciences, healthcare services and healthcare information technology. These companies must have highly differentiated products or services that represent substantial innovation over existing practices. While these investments are typically primarily in early stage companies, Versant has and will occasionally invest in later stage companies with the right attributes. www.versantventures.com

 

jVEN Capital, LLC

jVEN Capital, LLC is a venture capital and investment management company focused on the Life Sciences. The company is active in the areas of personalized medicine, genetics, medical devices, and specialty therapeutics. Established in 2007 by Evan Jones, a successful entrepreneur in the molecular diagnostics field, jVEN Capital works closely with its portfolio companies to help develop their visions into substantial businesses to meet unmet medical needs. Current investments include OpGen Inc., Signature Genomic Laboratories, LLC, Veracyte Inc, and CAS Medical Systems Inc.

 

Mason Wells

Mason Wells is a highly experienced and one of the leading private equity investors in the Midwestern United States. Founded in 1982 as a subsidiary of Marshall & Ilsley Corporation, Mason Wells became an independent firm in 1998. Since 1982, we have invested in three specific industry sectors: engineered products and services (including biomedical); outsourced business services (including healthcare); and specialty paper and packaging. The two key aspects of every transaction that we focus on are the management team and opportunities to build and improve a business. We work in partnerships with experienced, entrepreneurial management teams to implement our disciplined and proven Value Creation System to create long term sustainable value in companies. www.masonwells.com 

 

In-Q-Tel

In-Q-Tel identifies and partners with companies developing cutting-edge technologies to help deliver these solutions to the Central Intelligence Agency and the broader U.S. Intelligence Community (IC) to further their missions. To best serve its customers, In-Q-Tel plays multiple roles: a technology accelerator, fostering development and introduction of technologies needed by the Intelligence Community; a capabilities builder, helping nascent commercial technologies mature into commercial-off-the-shelf (COTS) products the government can buy; an idea lab and forum for innovation, providing the Intelligence Community with insight and access to both new technologies and leading innovators and thinkers; and a strategic investment firm, investing in companies and helping build businesses into reliable providers for the Intelligence Community. http://www.iqt.org/

“Physical map and genetic map still should be emphasized as an important parts of a reference genome. Recent progress in technologies, such as the whole genome mapping high-throughput platform offered by OpGen, now provide the tools for efficient physical map construction. This independent technology provides not only the validation of the genome sequencing, but also provides the large-scale chromosome structure information that cannot be detected by sequencing. We applied this technology as an assistant tool of the NGS to assemble bacterial, plant and large mammalian genome with reliable accuracy and generate the sub-chromosome graded assembly. The experience in these genome assembly projects shows that the physical map should be the standard for any reference genome to be assembled in further.”

Xun Xu, Ph.D.

Deputy Director at BGI
 

This independent technology provides not only the validation of the genome sequencing, but also provides the large-scale chromosome structure information that cannot be detected by sequencing.

Xun Xu, Ph.D.
Deputy Director at BGI

“Our research focuses on a wide variety of projects from viruses and microbes to crop plants and mammals. Many of our projects are de novo assembly projects, where, without a closely related genome sequence, it can be difficult to critically assess the results. We often combine different sequencing technologies, and we are finding that regardless of the sequencing platform, error correction, or assembler used, OpGen’s Whole Genome Mapping identifies misassemblies and provides the highest quality de novo assembly for further research.”

Matthew Clark, Ph.D.

Team Leader, Sequencing Technology Development

The Genome Analysis Centre (TGAC), Norwich, UK

OpGen’s Whole Genome Mapping identifies misassemblies and provides the highest quality de novo assembly for further research.

Matthew Clark, Ph.D.
Team Leader, Sequencing Technology Development

“We adopted OpGen’s Argus System as the most advanced way of adding Whole Genome Mapping to improve whole genome sequences. We combined Whole Genome Maps with sequence assemblies to correct errors and misassemblies in bacterial genome sequences as part of our program in the Human Microbiome Project. We are now moving the technology into larger genome projects.”


George Weinstock, Ph.D.

Associate Director
 The Genome Institute at Washington University

We combined Whole Genome Maps with sequence assemblies to correct errors and misassemblies in bacterial genome sequences. This is part of our program from the Human Microbiome Project.

George Weinstock Ph.D.

Associate Director

The Genome Institute at Washington University

“Certain things you just have a tough time answering with de novo sequencing. And assembly doesn’t always work out as sweetly as you would like. So definitely for any whole genome de novo project that people are insistent on closing we would do a Whole Genome Map optically as well as de novo assembly. And the amount of money you would save is in the thousands of dollars in finishing.”

Stefan Green

Director of DNA Services

University of Illinois Chicago Research Resources Center (UIC RRC)

Definitely for any whole genome de novo project that people are insistent on closing we would do a Whole Genome Map.

Stefan Green
Director of DNA Services

“Physical map and genetic map still should be emphasized as an important parts of a reference genome. Recent progress in technologies, such as the whole genome mapping high-throughput platform offered by OpGen, now provide the tools for efficient physical map construction. This independent technology provides not only the validation of the genome sequencing, but also provides the large-scale chromosome structure information that cannot be detected by sequencing. We applied this technology as an assistant tool of the NGS to assemble bacterial, plant and large mammalian genome with reliable accuracy and generate the sub-chromosome graded assembly. The experience in these genome assembly projects shows that the physical map should be the standard for any reference genome to be assembled in further.”

Xun Xu, Ph.D.

Deputy Director at BGI
 

This independent technology provides not only the validation of the genome sequencing, but also provides the large-scale chromosome structure information that cannot be detected by sequencing.

Xun Xu, Ph.D.
Deputy Director at BGI

“Our research focuses on a wide variety of projects from viruses and microbes to crop plants and mammals. Many of our projects are de novo assembly projects, where, without a closely related genome sequence, it can be difficult to critically assess the results. We often combine different sequencing technologies, and we are finding that regardless of the sequencing platform, error correction, or assembler used, OpGen’s Whole Genome Mapping identifies misassemblies and provides the highest quality de novo assembly for further research.”

Matthew Clark, Ph.D.

Team Leader, Sequencing Technology Development

The Genome Analysis Centre (TGAC), Norwich, UK

OpGen’s Whole Genome Mapping identifies misassemblies and provides the highest quality de novo assembly for further research.

Matthew Clark, Ph.D.
Team Leader, Sequencing Technology Development

“We adopted OpGen’s Argus System as the most advanced way of adding Whole Genome Mapping to improve whole genome sequences. We combined Whole Genome Maps with sequence assemblies to correct errors and misassemblies in bacterial genome sequences as part of our program in the Human Microbiome Project. We are now moving the technology into larger genome projects.”


George Weinstock, Ph.D.

Associate Director
 The Genome Institute at Washington University

We combined Whole Genome Maps with sequence assemblies to correct errors and misassemblies in bacterial genome sequences. This is part of our program from the Human Microbiome Project.

George Weinstock Ph.D.

Associate Director

The Genome Institute at Washington University

“Certain things you just have a tough time answering with de novo sequencing. And assembly doesn’t always work out as sweetly as you would like. So definitely for any whole genome de novo project that people are insistent on closing we would do a Whole Genome Map optically as well as de novo assembly. And the amount of money you would save is in the thousands of dollars in finishing.”

Stefan Green

Director of DNA Services

University of Illinois Chicago Research Resources Center (UIC RRC)

Definitely for any whole genome de novo project that people are insistent on closing we would do a Whole Genome Map.

Stefan Green
Director of DNA Services

CLOSE